SPY756.59−0.42%QQQ684.39−0.87%BTC/USD73,871.12+0.24%DIA524.02−0.08%GLD365.26+0.02%TLT80.87−0.06%

Kymera Therapeutics Inc

KYMRNASDAQ

Trade with Public

$134.84

-1.80-1.32%

Last update: Nov 11, 4:00 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Kymera Therapeutics (KYMR) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Kymera Therapeutics (KYMR) stock.

Analyst Consensus — 23 Analysts

19Buy

4Hold

# Analysts23

Latest Upgrades and Downgrades for Kymera Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Barclays	Eliana Merle	PT Raise	Overweight	$139→$170
—	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$136→$150
—	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$112→$116
—	BTIG	Jeet Mukherjee	PT Raise	Buy	$134→$139
—	Morgan Stanley	James Quigley	PT Raise	Overweight	$135→$146
—	Raymond James	Thomas Deal	Initiate	Outperform	$140
—	Citigroup	Geoff Meacham	PT Raise	Buy	$135→$150
—	Stifel	Alex Thompson	PT Raise	Buy	$132→$152
—	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$123→$144
—	Wolfe Research	Andy Chen	Upgrade	Peer Perform→Outperform	—
—	Guggenheim	Brad Canino	PT Raise	Buy	$135→$170
—	Wells Fargo	Derek Archila	PT Raise	Overweight	$116→$151
—	Barclays	Eliana Merle	PT Raise	Overweight	$133→$139
—	Deutsche Bank	David Hoang	Initiate	Hold	$120
—	Guggenheim	Brad Canino	PT Raise	Buy	$125→$135
—	Mizuho	Joseph Catanzaro	PT Raise	Outperform	$120→$140
—	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$106→$115
—	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$110→$125
—	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$116→$136
—	B. Riley Securities	Kalpit Patel	PT Raise	Buy	$117→$155

Kymera Therapeutics Inc

Kymera Therapeutics (KYMR) Stock Price Target 2026

Latest Upgrades and Downgrades for Kymera Therapeutics Stock

Kymera Therapeutics (KYMR) Stock Price Target 2026

Latest Upgrades and Downgrades for Kymera Therapeutics Stock

Analyst Ratings News

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Kymera Therapeutics Inc

Kymera Therapeutics (KYMR) Stock Price Target 2026

Latest Upgrades and Downgrades for Kymera Therapeutics Stock

Kymera Therapeutics (KYMR) Stock Price Target 2026

Latest Upgrades and Downgrades for Kymera Therapeutics Stock

Analyst Ratings News

PROBarclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PROTruist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRORBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PROBTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PROMorgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

People Also Watch

People Also Watch

Analyst Ratings News

PROBarclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PROTruist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRORBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PROBTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PROMorgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $170

PRO
Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

PRO
RBC Capital Maintains Sector Perform on Kymera Therapeutics, Raises Price Target to $116

PRO
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $139

PRO
Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146